Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

Debt (Tables)

12 Months Ended

Dec. 31, 2014

The following table summarizes the Company´s financial obligations for the next five years and thereafter as of December 31, 2014:


	2015		2016		2017		2018		2019		Thereafter		Total
Bank loan, including accrued interest	$	1,270,605	$	–	$	–	$	–	$	–	$	–	$	1,270,605

The Company recorded related-party interest expense concerning the Bridge Loan in the amounts set forth in the table below:


	Years ended December 31,
	2014		2013
Orbimed Private Investments III, LP	$	63,955	$	78,411
The Global Life Science Ventures Funds		57,709		70,131
Gilde Europe Food & Agribusiness Fund B.V.		54,158		67,083
Coöperative AAC LS U.A. (Forbion B.V.)		28,288		34,930

Sum of related-party interest expense relating to the Convertible Bridge Loan	$	204,110	$	250,556